tradingkey.logo
tradingkey.logo

Quantum-Si Inc

QSI
0.742USD
-0.067-8.26%
Close 03/30, 16:00ETQuotes delayed by 15 min
9.83MMarket Cap
LossP/E TTM

Quantum-Si Inc

0.742
-0.067-8.26%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Quantum-Si Inc

Currency: USD Updated: 2026-03-27

Key Insights

Quantum-Si Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 175 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 2.50.In the medium term, the stock price is expected to trend down.The company has shown very weak stock market performance over the past month, in line with its fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Quantum-Si Inc's Score

Industry at a Glance

Industry Ranking
175 / 391
Overall Ranking
313 / 4542
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Quantum-Si Inc Highlights

StrengthsRisks
Quantum-SI Incorporated is a life sciences company. The Company has designed and developed a hardware, consumable and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins. Its launched product consists of Platinum, the Platinum Analysis Software and consumables. Its flagship protein sequencing instrument, Platinum, is designed to make the power of single-molecule detection and NGPS accessible. Platinum is designed to provide a streamlined workflow compared to legacy MS workflows. Platinum uses its proprietary semiconductor chip that leverages time-domain sequencing with an initial focus on NGPS for an unbiased view of the proteome.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 125.14% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 2.44M.
Overvalued
The company’s latest PE is -1.49, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 61.41M shares, increasing 1.98% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 352.84K shares of this stock.

Analyst Rating

Based on 3 analysts
Buy
Current Rating
2.500
Target Price
+209.14%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Quantum-Si Inc is 5.71, ranking 328 out of 391 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 451.00K, representing a year-over-year decrease of 62.16%, while its net profit experienced a year-over-year decrease of 46.83%.

Score

Industry at a Glance

Previous score
5.71
Change
0

Financials

6.59

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

7.68

Operational Efficiency

2.72

Growth Potential

4.47

Shareholder Returns

7.11

Quantum-Si Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Quantum-Si Inc is 7.00, ranking 186 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.49, which is -32.99% below the recent high of -1.00 and -307.85% above the recent low of -6.08.

Score

Industry at a Glance

Previous score
7.00
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 175/391
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Quantum-Si Inc is 7.33, ranking 299 out of 391 in the Biotechnology & Medical Research industry. The average price target is 2.50, with a high of 4.00 and a low of 2.00.

Score

Industry at a Glance

Previous score
7.33
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 3 analysts
Buy
Current Rating
2.500
Target Price
+227.18%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

548
Total
6
Median
6
Average
Company name
Ratings
Analysts
Quantum-Si Inc
QSI
3
CRISPR Therapeutics AG
CRSP
29
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Beigene Ltd
ONC
24
Intellia Therapeutics Inc
NTLA
24
1
2
3
...
110

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Quantum-Si Inc is 5.23, ranking 323 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 0.99 and the support level at 0.65, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
5.15
Change
0.08

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(3)
Neutral(1)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.025
Sell
RSI(14)
32.223
Neutral
STOCH(KDJ)(9,3,3)
8.809
Oversold
ATR(14)
0.061
Low Volatility
CCI(14)
-149.843
Sell
Williams %R
96.346
Oversold
TRIX(12,20)
-0.718
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Sell(6)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MA5
0.805
Sell
MA10
0.844
Sell
MA20
0.898
Sell
MA50
1.000
Sell
MA100
1.170
Sell
MA200
1.405
Sell

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Quantum-Si Inc is 3.00, ranking 195 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 31.40%, representing a quarter-over-quarter increase of 4.33%. The largest institutional shareholder is The Vanguard, holding a total of 9.61M shares, representing 4.89% of shares outstanding, with 16.05% increase in holdings.

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
Rothberg (Jonathan M)
13.73M
--
BlackRock Institutional Trust Company, N.A.
10.47M
+4.79%
The Vanguard Group, Inc.
Star Investors
8.71M
+0.52%
ARK Investment Management LLC
Star Investors
7.62M
-4.23%
Amova Asset Management Co., Ltd.
5.22M
-7.18%
Geode Capital Management, L.L.C.
3.75M
+8.68%
State Street Investment Management (US)
2.82M
+2.21%
Hawkins (Jeffrey Alan)
1.86M
-1.26%
Rakin (Kevin L)
2.92M
+0.23%
1
2

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Quantum-Si Inc is 2.70, ranking 205 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 3.08. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Score

Industry at a Glance

Previous score
2.70
Change
0
Beta vs S&P 500 index
3.04
VaR
+8.78%
240-Day Maximum Drawdown
+70.95%
240-Day Volatility
+95.64%

Return

Best Daily Return
60 days
+14.26%
120 days
+24.55%
5 years
+119.59%
Worst Daily Return
60 days
-9.50%
120 days
-10.24%
5 years
-32.15%
Sharpe Ratio
60 days
-1.96
120 days
-1.13
5 years
+0.14

Risk Assessment

Maximum Drawdown
240 days
+70.95%
3 years
+83.73%
5 years
+95.33%
Return-to-Drawdown Ratio
240 days
-0.55
3 years
-0.18
5 years
-0.19
Skewness
240 days
+1.21
3 years
+4.70
5 years
+4.56

Volatility

Realised Volatility
240 days
+95.64%
5 years
+114.81%
Standardised True Range
240 days
+16.44%
5 years
+32.30%
Downside Risk-Adjusted Return
120 days
-266.27%
240 days
-266.27%
Maximum Daily Upside Volatility
60 days
+65.32%
Maximum Daily Downside Volatility
60 days
+46.81%

Liquidity

Average Turnover Rate
60 days
+4.10%
120 days
+4.19%
5 years
--
Turnover Deviation
20 days
-16.63%
60 days
-4.49%
120 days
-2.48%

Peer Comparison

Biotechnology & Medical Research
Quantum-Si Inc
Quantum-Si Inc
QSI
5.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
Alkermes Plc
ALKS
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals Inc
MDGL
8.27 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals Inc
BCRX
8.27 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Day One Biopharmaceuticals Inc
Day One Biopharmaceuticals Inc
DAWN
8.26 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQVIA Holdings Inc
IQV
8.21 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI